Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus

MLA

Akseli Hemminki, et al. Supplementary Figure 4 from Antiviral and Antitumor T-Cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....964142a8000d7d7739d911ff1b46f367&authtype=sso&custid=ns315887.

APA

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, Timo Joensuu, Saila Pesonen, Raita Heiskanen, Minna Oksanen, Siri Tähtinen, Ilkka Liikanen, Vincenzo Cerullo, Anniina Koski, Iulia Diaconu, Petri Nokisalmi, & Anna Kanerva. (2023). Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus.

Chicago

Akseli Hemminki, Lotta Kangasniemi, Sari Pesonen, Kalevi Kairemo, Leena Laasonen, Kaarina Partanen, Tuomo Alanko, et al. 2023. “Supplementary Figure 4 from Antiviral and Antitumor T-Cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....964142a8000d7d7739d911ff1b46f367&authtype=sso&custid=ns315887.